351 related articles for article (PubMed ID: 1938508)
21. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Graf R; Wust P; Hildebrandt B; Gögler H; Ullrich R; Herrmann R; Riess H; Felix R
Oncology; 2003; 65(1):14-22. PubMed ID: 12837978
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
23. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.
John M; Pajak T; Flam M; Hoffman J; Markoe A; Wolkov H; Paris K
Cancer J Sci Am; 1996; 2(4):205-11. PubMed ID: 9166533
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Myerson RJ; Outlaw ED; Chang A; Birnbaum EH; Fleshman JW; Grigsby PW; Kodner IJ; Malayapa RS; Mutch MG; Parikh P; Picus J; Tan BR
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):428-35. PubMed ID: 19251377
[TBL] [Abstract][Full Text] [Related]
25. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
[TBL] [Abstract][Full Text] [Related]
26. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Valentini V; Coco C; Cellini N; Picciocchi A; Fares MC; Rosetto ME; Mantini G; Morganti AG; Barbaro B; Cogliandolo S; Nuzzo G; Tedesco M; Ambesi-Impiombato F; Cosimelli M; Rotman M
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):371-83. PubMed ID: 11567811
[TBL] [Abstract][Full Text] [Related]
27. Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
Provencher S; Oehler C; Lavertu S; Jolicoeur M; Fortin B; Donath D
Radiat Oncol; 2010 May; 5():41. PubMed ID: 20492729
[TBL] [Abstract][Full Text] [Related]
28. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
29. [Outcome of simultaneous radiochemotherapy of anal carcinoma].
Fraunholz IB; Adamietz IA; Lorenz M; Staib-Sebler E; Böttcher HD
Zentralbl Chir; 1997; 122(1):39-43. PubMed ID: 9133135
[TBL] [Abstract][Full Text] [Related]
30. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
[TBL] [Abstract][Full Text] [Related]
31. Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
Smith DE; Shah KH; Rao AR; Frost DB; Latino F; Anderson PJ; Peddada AV; Kagan AR
Radiology; 1994 May; 191(2):569-72. PubMed ID: 8153343
[TBL] [Abstract][Full Text] [Related]
32. Anal canal cancer: current treatment and results.
Cummings BJ
Ann Acad Med Singap; 1996 May; 25(3):460-7. PubMed ID: 8876916
[TBL] [Abstract][Full Text] [Related]
33. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
Weber DC; Kurtz JM; Allal AS
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):675-80. PubMed ID: 11395235
[TBL] [Abstract][Full Text] [Related]
34. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
35. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Meropol NJ; Niedzwiecki D; Shank B; Colacchio TA; Ellerton J; Valone F; Budinger S; Day JM; Hopkins J; Tepper J; Goldberg RM; Mayer RJ
J Clin Oncol; 2008 Jul; 26(19):3229-34. PubMed ID: 18490648
[TBL] [Abstract][Full Text] [Related]
36. [Radiochemotherapy in anal canal epidermoid cancer].
Peiffert D
Ann Chir; 2000 Oct; 125(8):717-25. PubMed ID: 11105342
[TBL] [Abstract][Full Text] [Related]
37. Radiochemotherapy for anal carcinoma - effectivity and late toxicity.
Mai SK; Grieger J; Lachmann R; Bohrer M; Tiefenbacher U; Wenz F
Onkologie; 2002 Feb; 25(1):55-9. PubMed ID: 11893884
[TBL] [Abstract][Full Text] [Related]
38. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
39. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
[TBL] [Abstract][Full Text] [Related]
40. [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
Grabenbauer GG; Panzer M; Hültenschmidt B; Döker R; Huber K; Kuhne-Velte HJ; Hutter M; Rühl U; Budach V; Wendt T
Strahlenther Onkol; 1994 Jul; 170(7):391-9. PubMed ID: 8052938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
